- Home
- RMR vs ZNTL Comparison
RMR vs ZNTL Comparison
Compare RMR & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMR | ZNTL |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.2M | 289.0M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RMR | ZNTL |
|---|---|---|
| Price | $18.53 | $2.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $19.00 | $6.60 |
| AVG Volume (30 Days) | 71.9K | ★ 832.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.37% | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $700,284,000.00 | N/A |
| Revenue This Year | $259.61 | N/A |
| Revenue Next Year | $2.45 | N/A |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.27 | $1.21 |
| 52 Week High | $21.45 | $6.95 |
Technical Indicators
Market Signals| Indicator | RMR | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 37.11 | 22.91 |
| Support Level | $17.88 | $2.09 |
| Resistance Level | $20.52 | $4.06 |
| Average True Range (ATR) | 0.37 | 0.21 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 9.33 | 4.14 |
Price Performance
Historical ComparisonAbout RMR The RMR Group Inc.
The RMR Group Inc is a U.S. based real estate investment manager engaged in commercial real estate, private capital, and credit strategies. Its portfolio covers various commercial real estate asset classes, and it manages investments across various industries, geographies and asset classes.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.